Highlights 

  • FDA extends decision date for Ascendis Pharma’s TransCon CNP to February 28, 2026 
  • Extension aims to review additional post-marketing requirement information 
  • TransCon CNP offers once-weekly dosing versus daily dosing for BioMarin’s Voxzogo 
  • Achondroplasia affects more than 250,000 people worldwide 
  • ASND shares closed 2.38% lower at USD 206.65 on Tuesday 

Ascendis Pharma A/S (NASDAQ: ASND) reported that the U.S.Food and Drug Administrationhas extended the decision deadline for its investigational therapy, TransCon CNP (Navepegritide), by three months. The new Prescription Drug User Fee Act date is now set for February 28, 2026, instead of the earlier November 30, 2025, timeline. 

According to the company, the FDA requires additional time to assess recently submitted post-marketing requirement materials delivered on November 5, 2025. Such extensions are not uncommon, especially when agencies need further clarification on long-term data, safety projections, or commitments tied to future studies. 

Understanding Achondroplasia and Treatment Landscape 

Achondroplasia, the most common form of dwarfism, is a rare genetic condition affecting more than 250,000 individuals globally. It results from mutations impacting bone growth and leads to disproportionate short stature. The condition also brings a wide spectrum of complications, including muscular, neurological, and cardiorespiratory issues that often require lifelong management. 

Currently, BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) Voxzogo (vosoritide) remains the only FDA-approved drug for pediatric patients with achondroplasia. Voxzogo requires once-daily subcutaneous injections, which, while effective, create adherence challenges for families managing long-term treatment routines. 

TransCon CNP’s Potential Differentiation 

Ascendis Pharma’s TransCon CNP is designed as a once-weekly subcutaneous injection, offering a potentially more convenient dosing schedule. As an investigational prodrug of C-type natriuretic peptide, the therapy aims to provide sustained release and consistent exposure. If approved, it could become an appealing alternative for families seeking a less frequent and easier-to-manage regimen. 

Conclusion 

The FDA’s extension of the TransCon CNP review period places additional attention on Ascendis Pharma’s efforts to introduce a new treatment option for children with achondroplasia. While the delay signals deeper regulatory scrutiny, it also underscores the significance of long-term safety and efficacy data in this therapeutic category. A once-weekly therapy could reshape the treatment experience for many families, making the forthcoming FDA decision pivotal for both the company and the broader achondroplasia community.  

Ascendis Pharmas’ shares closed at USD 210.01, marking a 1.63% increase from the prior session.